Newsroom

UTRECHT, Países Bajos--(BUSINESS WIRE)--Loomis, Sayles & Company, la gestora de inversiones centenaria con 363 800 millones de euros en activos bajo gestión, celebra el quinto aniversario de sus estrategias Loomis Sayles Euro Credit y Loomis Sayles Euro High Yield. El equipo de crédito europeo de Loomis Sayles, liderado por los codirectores y gestores de cartera Rik den Hartog y Pim van Mourik Broekman, gestiona 3500 millones de euros en activos con tres estrategias diferentes. Respaldado p...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday...

DALLAS--(BUSINESS WIRE)--Sunoco LP (NYSE: SUN) (“Sunoco” or the “Partnership”) today announced that it has priced at 100% a private offering (the “offering”) of 5.375% senior notes due 2031 in an aggregate principal amount of $600 million (the “2031 notes”) and 5.625% senior notes due 2034 in an aggregate principal amount of $600 million (the “2034 notes,” and collectively with the 2031 notes, the “notes”). The offering was upsized from an initial offering size of $500 million aggregate princip...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Sues FL Health Dept. to Block Emergency Rule Cutting HIV Drug Access for Thousands...

UTRECHT, Nederland--(BUSINESS WIRE)--Loomis, Sayles & Company, de honderd jaar oude vermogensbeheerder met € 363,8 miljard aan beheerd vermogen, viert het vijfjarig bestaan van zijn Loomis Sayles Euro Credit- en Loomis Sayles Euro High Yield-strategieën. Het Loomis Sayles Euro Credit Team, onder leiding van co-hoofden en portfoliomanagers Rik den Hartog en Pim van Mourik Broekman, beheert € 3,5 miljard aan vermogen verdeeld over drie strategieën. Gesteund door de toonaangevende technologisc...

舊金山--(BUSINESS WIRE)--(美國商業資訊)-- Andersen Consulting宣布與總部位於義大利的公司Aesys達成合作協議，強化其在技術和系統整合領域的服務能力。 Aesys成立於2013年，是一家數位技術和系統整合公司，致力於提供端對端IT解決方案。該公司將軟體發展、雲端運算、機器學習和網路安全方面的專業能力與在銀行和汽車系統整合領域的卓越記錄相結合，協助企業加快數位化轉型和強化技術基礎設施。 Aesys國際業務經理Samuel Roberto表示：「透過本次合作，我們可以將自身深厚的系統整合專業能力與Andersen Consulting的全球平台相結合，為客戶創造更大價值。我們將攜手協助企業強化技術基礎，在機器學習和網路安全等領域採用創新解決方案，實現永續的數位化轉型。」 Andersen全球董事長兼執行長Mark L. Vorsatz表示：「與Aesys達成的這項協議對Andersen Consulting而言是天然的契合。他們在系統整合領域的卓越傳承，加上近期向先進技術服務的擴展，提升了我們為正在進行數位化轉型的客戶所提供的價值。」 Anders...

LADERA RANCH, Calif.--(BUSINESS WIRE)--Strategic Storage Trust VI, Inc. (“SST VI”), a publicly registered non-traded real estate investment trust sponsored by an affiliate of SmartStop Self Storage REIT, Inc. (“SmartStop”) (NYSE: SMA), announced the opening of a new Class A self-storage facility in Toronto, Ontario. Located at 1983 Kipling Ave., the new facility reflects the company’s long-term commitment to growing its Canadian platform through high-quality development in dense, supply-constra...

KRAKOW, Poland & SEATTLE--(BUSINESS WIRE)--CMT is one of the first major AdTech platforms to break from consensus-based geolocation models and adopt accuracy-first, evidence-driven IP data....

洛杉磯--(BUSINESS WIRE)--(美國商業資訊)-- 臨床階段生物製藥公司Kairos Pharma, Ltd. (NYSE American: KAPA) 專事開發創新癌症療法。該公司今天宣布與Celyn Therapeutics, Inc.簽署投資條件書，以戰略性收購後者的研發資產。Celyn Therapeutics, Inc.是一家由OrbiMed和Torrey Pines Investment投資成立的私營生物科技公司。根據擬議的協議條款，Kairos Pharma將收購Celyn Therapeutics, Inc.旗下兩項臨床階段腫瘤藥物的全球權利，這兩項高度差異化的藥物均靶向非小細胞肺癌 (NSCLC)：「CL-273」是一種處於前臨床試驗申請 (IND) 階段的可逆性、不影響野生型基因的泛EGFR抑制劑；「CL-741」則是一種已進入1期臨床試驗的口服IIb型c-MET激酶抑制劑。 Kairos Pharma執行長John Yu醫學博士表示：「我們預計這次收購將顯著擴大本公司的腫瘤產品，加入處於晚期臨床前和已進入I期臨床試驗階段的候選藥物。這些藥物面向價值...

洛杉矶--(BUSINESS WIRE)--(美国商业资讯)-- Kairos Pharma, Ltd.（NYSE American：KAPA）是一家专注于创新癌症疗法研发的临床阶段生物制药公司。公司今日宣布，已与Celyn Therapeutics, Inc.签署战略资产收购条款清单。Celyn Therapeutics为一家获得OrbiMed与Torrey Pines Investment支持的私营生物技术企业。根据拟议交易条款，Kairos Pharma将取得两项具备显著差异化优势的临床阶段肿瘤资产的全球权益，相关产品均聚焦非小细胞肺癌（NSCLC）治疗领域。其中，CL-273为一款处于IND申报前阶段的可逆性泛EGFR抑制剂，具备保留野生型EGFR活性的特性；CL-741则为一款已具备I期临床启动条件的口服IIb型c-MET激酶抑制剂。 Kairos Pharma首席执行官John Yu医学博士表示：“我们预计，此次收购将为公司肿瘤产品管线带来重要拓展，引入处于后期临床前阶段及已具备I期临床启动条件的创新资产，切入一个规模达数十亿美元、且仍存在显著未满足医疗需求的市场领域。若本...